Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

PARP inhibitors

15 evidence topics · 14 sources

Olaparib monotherapy: PROfound efficacy, cohort A
OutcomeOlaparib (n=162)Enzalutamide or abiraterone acetate (n=83)
Median rPFS, months (95% CI)“7.4 (6.2, 9.3)”“3.6 (1.9, 3.7)”
rPFS hazard ratio (95% CI)“0.34 (0.25, 0.47)”Not applicable
Median OS, months (95% CI)“19.1 (17.4, 23.4)”“14.7 (11.9, 18.8)”
OS hazard ratio (95% CI)“0.69 (0.50, 0.97)”Not applicable
Rucaparib: TRITON3 efficacy, BRCA-mutated subgroup
OutcomeRucaparib (N=201)Androgen receptor pathway inhibitor or docetaxel (N=101)
Median rPFS, months (95% CI)“11.2 (9.2-13.8)”“6.4 (5.4-8.3)”
rPFS hazard ratio (95% CI)“0.50 (0.36, 0.69)”Not applicable
Median OS, months (95% CI)“23.2 (19.1, 25.2)”“21.2 (18.0, 23.1)”
OS hazard ratio (95% CI)“0.91 (0.68, 1.20)”Not applicable
Overall response rate, % (95% CI)“45.1 (34.1, 56.5)”“17.1 (7.2, 32.1)”
First-line combination: talazoparib with enzalutamide
Outcome (TALAPRO-2, HRR gene-mutated)Talazoparib with enzalutamide (N=200)Placebo with enzalutamide (N=199)
Median rPFS by BICR, months (95% CI)“NR (21.9, NR)”“13.8 (11.0, 16.7)”
rPFS hazard ratio (95% CI)“0.45 (0.33, 0.61)”Not applicable
Median OS, months (95% CI)“45.1 (35.4, NR)”“31.1 (27.3, 35.4)”
OS hazard ratio (95% CI)“0.62 (0.48, 0.81)”Not applicable